NH Hospital's innovative approach to mental health is based on the patient's biochemical makeup and gene-environment interfaces. Photo courtesy of NH Hospital

There's no one-size-fits-all solution to medical care. NH Hospital is bringing innovative technologies and functional medicine to patients in the Houston area. Using patients' biochemical makeup, the medical provider has created a unique service for Houstonians seeking a multi-pronged approach to behavioral health and substance use disorders.

The past year has been an incubator for mental health issues. Pandemic isolation, social distancing, financial instability, racial reckonings, and a massive death toll have posed an enormous threat to the mental wellbeing of people around the world. Experts predict a long-term spike in post-traumatic stress disorder (PTSD) cases as society grapples with the tragedies of the last year, but the toll is already here.

A recent Centers for Disease Control and Prevention (CDC) study found that the percentage of adults with recent symptoms of anxiety or depression increased from 36.4 to 41.5 percent between Aug. 19, 2020, and Feb. 1, 2021.

As the world waits for a moment to exhale after a catastrophic year, NH Hospital keeps busy serving patients struggling with both behavioral health and addiction during the pandemic. Outside of depression and anxiety, the facility also treats bipolar disorder, PTSD, codependency, and postpartum depression by using a multidisciplinary approach.

NH Hospital integrates traditional medicine with functional medicine with a mission of treating the root cause of an issue and not just the symptoms. From providing an on-site chef and nutritionist to stimulating patients with calming acoustic therapy, the facility blends unique treatment modalities that address the whole body rather than an isolated issue.

"With functional medicine, we find other avenues and ways to allow [patients] to heal and to change their behavior," explains Debbie Cormier, CEO of NH Hospital.

Using genetic markers as a roadmap to health

You can build the closet of Carrie Bradshaw's dreams online, buy bespoke cologne based on your body chemistry, monogram jewelry and clothing, and even get a Renaissance-style portrait of your family pet. Tailor-made options are ubiquitous; why not customize medical care?

"For years, the traditional way, we just gave people the same amount of meds, the same diets, the same everything," and wondered why some patients responded better or quicker than others, explains Cormier. For the unlucky patients who didn't get stellar results, she says doctors may have thought "they just have to deal with it" and wait. "We don't feel that you should have to just deal with it," she continues.

When treating a patient, NH Hospital doctors consider the genetic makeup of each patient to create a custom care plan. With tests as simple as a swab of the cheek, the facility can gather biochemical markers that can share valuable medical information like risk factors for diseases.

Cormier believes NH Hospital's ability to look at a patient's genetic background and "treat you as an individual," is a key factor that sets the facility apart. The hospital also focuses on understanding how your genes interact with your environment.

Think of gene-environment interactions as nature vs. nurture, an ideology that research suggests plays significant roles in the outset of mental illness. Genetic and environmental factors interact to influence phenotype, the observable characteristics you exhibit when your genotype and environment interact.

When these factors are off-balance, it can result in undesirable results. A 2001 study of Finnish twins studied the socio-geographic impact on adolescent alcohol use in urban and rural environments. While the frequency of alcohol use was the same in both settings, the factors that led adolescents to drink were entirely different. Genetic factors played a larger role in urban areas, whereas the shared environment had a greater influence in rural settings.

By applying various modalities based on genetic information, doctors aren't going in blind and "know you from the inside out," says Cormier.

When a patient comes in struggling with something as grappling as depression or anxiety, conditions they've seen an uptick in since the beginning of the pandemic, doctors will run a genetic test as well as traditional lab work. Cormier says some potential treatment paths may include photosynthesis therapy, hydration therapy and nutrition.

Dietetics meets tech

NH Hospital helps patients get micronutrient infusions, but its nutrition program provides an integrated approach to fueling the body with the help of a staff chef.

"We only have so much energy every day, and we choose how we use the energy but by getting your diet right, it starts to heal you in all kinds of ways," says Cormier.

While the physical repercussions of a poor diet like diabetes and heart disease are widely known, you may be surprised to hear that nutrition can affect mood disorders and harm brain cells. According to Harvard Health Publishing, refined sugars can lead to brain impairment, depression and oxidative stress — the free radicals produced when the body uses oxygen, which can damage cells. By focusing on a patient's nutrition, "the person has a better chance to heal, not only from the issue that is brought to us but to overall feel good," she says.

Counseling, cryotherapy, transcranial magnetic stimulation and cocoon therapy therapies are just some of the other methods NH Hospital doctors use to treat their patients.

Cormier recalls the recovery of a patient who was experiencing depression and using a wheelchair due to pain in her knees. She gradually gained the ability to walk without pain again after a months-long treatment plan of cryotherapy and micronutrient infusions.

"She said that we really changed her life because we gave her back her life. Now she's walking a mile a day around her block and she's able to do daily moving. She said she hadn't done that in years," says Cormier.

A mission to heal

Outside of neuropsychology, NH Hospital offers medical detox with monitoring from trained professionals and therapy plans for patients coming off of alcohol, methamphetamine, heroin, opioids like fentanyl and other prescription drugs.

Since the U.S. The Department of Health and Human Services declared the opioid epidemic as a public health emergency in 2017, nearly 841,000 people have died of an opioid overdose. Like anxiety and depression, addiction is also on the rise during the pandemic. A CDC survey found that 13 percent of respondents began using drugs during the pandemic or increased their use of illicit substances.

NH Hospital doctors provide micronutrients among other aides to help "build [patients] up] before taking them off the drugs, says Cormier. "We're just trying to make sure the patient feels safe and that if we're doing all these things, we continue to move them in a positive direction instead of just letting them sweat it out," she says.

"Our leadership here is committed to doing what it takes to help people whether they have behavioral, medical, or whatever [condition] brings them through our doors so that we make them have a better life," says Cormier.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.